diabeticmediterraneandiet.com
FDA Advisory Panel to Look at Rosiglitazone Once Again
Larry Husten writing at Forbes has the details. For example:Battle lines are being drawn two weeks before a highly unusual two-day FDA advisory committee meeting to discuss the contentious diabetes…